These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 11848649

  • 1. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
    Endrikat J, Gerlinger C, Cronin M, Wessel J, Ruebig A, Rosenbaum P, Düsterberg B.
    Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
    [Abstract] [Full Text] [Related]

  • 2. Blood pressure stability in a normotensive population during intake of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 g gestodene.
    Endrikat J, Gerlinger C, Cronin M, Ruebig A, Schmidt W, Düsterberg B.
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):159-66. PubMed ID: 11763980
    [Abstract] [Full Text] [Related]

  • 3. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
    Ferreira AC, Montes MB, Franceschini SA, Toloi MR.
    Int J Fertil Womens Med; 2001 Sep; 46(5):265-70. PubMed ID: 11720199
    [Abstract] [Full Text] [Related]

  • 4. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N.
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.
    Halbe HW, de Melo NR, Bahamondes L, Petracco A, Lemgruber M, de Andrade RP, da Cunha DC, Guazelli CA, Baracat EC.
    Eur J Contracept Reprod Health Care; 1998 Sep; 3(3):113-20. PubMed ID: 9853201
    [Abstract] [Full Text] [Related]

  • 6. [The effect of two low dose oral contraceptive with gestodene on the systems of natural inhibitors of coagulation].
    Uchikova E, Terzhumanov R, Milchev N, Iacheva T.
    Akush Ginekol (Sofiia); 2004 Sep; 43(6):19-23. PubMed ID: 15669648
    [Abstract] [Full Text] [Related]

  • 7. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
    Rechberger T, Tomaszewski J, Pieprzowska-Białek A, Kulik-Rechberger B, Skorupski P.
    Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792
    [Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
    Bilotta P, Favilli S.
    Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
    [Abstract] [Full Text] [Related]

  • 9. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene.
    Fuchs N, Düsterberg B, Weber-Diehl F, Mühe B.
    Contraception; 1995 Jun; 51(6):335-9. PubMed ID: 7554972
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical experience with a low-dose oral contraceptive containing gestodene.
    Düsterberg B, Brill K.
    Adv Contracept; 1990 Dec; 6 Suppl():37-49; discussion 50. PubMed ID: 2291446
    [Abstract] [Full Text] [Related]

  • 12. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T.
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [Abstract] [Full Text] [Related]

  • 13. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
    Nappi C, Di Spiezio Sardo A, Greco E, Tommaselli GA, Giordano E, Guida M.
    Obstet Gynecol; 2005 Jan; 105(1):53-60. PubMed ID: 15625142
    [Abstract] [Full Text] [Related]

  • 14. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC, Filho CI, Faggion D, Baracat EC.
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [Abstract] [Full Text] [Related]

  • 15. Added benefits of drospirenone for compliance.
    Foidart JM.
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML, Schmidt J.
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [Abstract] [Full Text] [Related]

  • 20. Effect of a low-dose ethinylestradiol and gestodene in combination on the frequency of micronuclei in human peripheral blood lymphocytes of healthy women in vivo.
    Loncar D, Milosević-Djordjević O, Zivanović A, Grujicić D, Arsenijević S.
    Contraception; 2004 Apr; 69(4):327-31. PubMed ID: 15033409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.